Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

68.88 +0.56 (+0.82%)
Streaming Delayed Price Updated: 2:48 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Why Antares Pharma Stock Is Soaring Today ↗
Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing... 
Via Benzinga
News headline image
Why Is Antares Pharma (ATRS) Stock Up Today? ↗
Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). 
Via InvestorPlace
News headline image
Benzinga's Daily Brief On Trending Tickers For April 13, 2022: JPMorgan, PayPal, Bed Bath & Beyond And More ↗
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
News headline image
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares ↗
GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
Halozyme, Chugai Ink $185M ENHANZE Technology Licensing Pact ↗
Halozyme Therapeutics Inc (NASDAQ: HALO) has  
Via Benzinga
News headline image
Earnings Scheduled For February 22, 2022 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report quarterly earnings at $0.13 per share on revenue of $439.63 million. • Sohu... 
Via Benzinga
News headline image
Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13 ↗
Reuters Blackrock To Introduce Its First China ETF In 2022: Reuters According to two people with close knowledge of the matter, BlackRock, Inc. (NYSE: BLK) plans to launch... 
Via Benzinga
News headline image
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
Janssen Partner Genmab Loses Arbitration Over Darzalex Royalties ↗
 
Via Benzinga
News headline image
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder ↗
Argenx SE (NASDAQ: ARGX) ) has  
Via Benzinga
News headline image
Halozyme's Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth ↗
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million.... 
Via Benzinga
News headline image
Halozyme Therapeutics: Q4 Earnings Insights ↗
Halozyme Therapeutics (NASDAQ:HALO) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 23.65% to $2.81 during Friday's regular session. As of 12:30 EST, BioLine Rx's stock is trading at a... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
News headline image
7 Best Drug Stocks to Buy for 2022 Without Covid Catalysts ↗
These seven drug stocks, a mix of growth, value, and moonshot plays, each stand to see big moves in the next twelve months. 
Via InvestorPlace
News headline image
Janssen's Subcutaneous Darzalex Combo Wins FDA Approval For Pretreated Multiple Myeloma ↗
Johnson & Johnson's (NYSE: JNJ) Janssen Biotech Inc has received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with... 
Via Benzinga
News headline image
Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook ↗
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q3 revenue of $115.8 million compared to $65.3 million a year ago, beating the consensus of $101.94 million.... 
Via Benzinga
News headline image
Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcript ↗
HALO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
News headline image
Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance ↗
Halozyme Therapeutics Inc (NASDAQ: HALO) reported Q2 revenue of $136.5 million compared to $55.2 million a year ago, beating the consensus of $103.16 million.... 
Via Benzinga
News headline image
Halozyme Therapeutics, inc (HALO) Q2 2021 Earnings Call Transcript ↗
HALO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
Halozyme Therapeutics: Q2 Earnings Insights ↗
Shares of Halozyme Therapeutics (NASDAQ:HALO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 247.37% over the... 
Via Benzinga
News headline image
Analyzing Halozyme Therapeutics's Unusual Options Activity ↗
On Friday, shares of Halozyme Therapeutics (NASDAQ:HALO) saw unusual options activity. After the option alert, the stock price moved down to $42.55. Sentiment: BEARISH Option... 
Via Benzinga
News headline image
Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma ↗
The FDA has approved Janssen Biotech Inc's, a unit of Johnson & Johnson (NYSE: JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for multiple... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.